<DOC>
	<DOC>NCT00407121</DOC>
	<brief_summary>Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.</brief_summary>
	<brief_title>Intravitreal Bevacizumab for Inflammatory Neovascular Membranes</brief_title>
	<detailed_description />
	<mesh_term>Choroiditis</mesh_term>
	<mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical Diagnose Patient Consent Chronic stage of inflammation only eye age lower than 30 yo. Systemic condition</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Neovascular Membrane</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>